Segment Information (Schedule Of Total Revenues Of Top Selling Products) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended				6 Months Ended
	Jun. 30, 2012		Jun. 30, 2011		Jun. 30, 2012		Jun. 30, 2011
Revenue, Major Customer [Line Items]
Revenues	$ 294,333		$ 224,188		$ 565,805		$ 457,140
Maximum percentage revenue of other products compared to generic products					3.00%		3.00%
Par Pharmaceutical [Member]
Revenue, Major Customer [Line Items]
Revenues	273,109		202,449		524,276		412,193
Par Pharmaceutical [Member] | Modafinil (Provigil) [Member]
Revenue, Major Customer [Line Items]
Revenues	57,484		0		57,484		0
Par Pharmaceutical [Member] | Metoprolol Succinate ER (Toprol-XL) [Member]
Revenue, Major Customer [Line Items]
Revenues	48,953		63,706		110,718		127,124
Par Pharmaceutical [Member] | Budesonide (Entocort EC) [Member]
Revenue, Major Customer [Line Items]
Revenues	33,513		16,357		71,497		16,357
Par Pharmaceutical [Member] | Propafenone (Rythmol SR) [Member]
Revenue, Major Customer [Line Items]
Revenues	17,888		13,311		36,980		35,350
Par Pharmaceutical [Member] | Sumatriptan succinate injection (Imitrex) [Member]
Revenue, Major Customer [Line Items]
Revenues	13,945		15,284		30,644		31,983
Par Pharmaceutical [Member] | Bupropion ER (Wellbutrin) [Member]
Revenue, Major Customer [Line Items]
Revenues	12,010		0		23,364		0
Par Pharmaceutical [Member] | Chlorpheniramine/Hydrocodone (Tussionex) [Member]
Revenue, Major Customer [Line Items]
Revenues	7,984		7,022		21,941		19,701
Par Pharmaceutical [Member] | Zolpidem (Ambien CR) [Member]
Revenue, Major Customer [Line Items]
Revenues	5,342		0		12,264		0
Par Pharmaceutical [Member] | Cholestyramine Powder (Questran) [Member]
Revenue, Major Customer [Line Items]
Revenues	4,958		4,077		9,878		7,760
Par Pharmaceutical [Member] | Tramadol ER (Ultracet ER) [Member]
Revenue, Major Customer [Line Items]
Revenues	4,593		5,873		10,422		11,954
Par Pharmaceutical [Member] | Dronabinol Marinol [Member]
Revenue, Major Customer [Line Items]
Revenues	4,444		8,118		12,047		14,989
Par Pharmaceutical [Member] | Meclizine Hydrochloride (Antivert) [Member]
Revenue, Major Customer [Line Items]
Revenues	3,783		4,562		7,969		9,437
Par Pharmaceutical [Member] | Amlodipine And Benazepril HCI (Lotrel) [Member]
Revenue, Major Customer [Line Items]
Revenues	1,729		12,505		4,177		30,675
Par Pharmaceutical [Member] | Nateglinide (Starlix) [Member]
Revenue, Major Customer [Line Items]
Revenues	3,518		3,815		7,542		8,120
Par Pharmaceutical [Member] | Other [Member]
Revenue, Major Customer [Line Items]
Revenues	46,170	[1]	38,774	[1]	95,160	[1]	81,809	[1]
Par Pharmaceutical [Member] | Other product related revenues [Member]
Revenue, Major Customer [Line Items]
Revenues	6,795	[2]	9,045	[2]	12,189	[2]	16,934	[2]
Par Pharmaceutical [Member] | Total Par Pharmaceutical Revenues [Member]
Revenue, Major Customer [Line Items]
Revenues	273,109		202,449		524,276		412,193
Strativa [Member]
Revenue, Major Customer [Line Items]
Revenues	21,224		21,739		41,529		44,947
Strativa [Member] | Other product related revenues [Member]
Revenue, Major Customer [Line Items]
Revenues	1,741	[2]	125	[2]	3,696	[2]	4,399	[2]
Strativa [Member] | Megace ES [Member]
Revenue, Major Customer [Line Items]
Revenues	14,212		14,050		26,390		28,135
Strativa [Member] | Nascobal Nasal Spray [Member]
Revenue, Major Customer [Line Items]
Revenues	5,380		6,274		11,312		10,152
Strativa [Member] | Oravig [Member]
Revenue, Major Customer [Line Items]
Revenues	(3)		1,027		152		1,776
Strativa [Member] | Zuplenz [Member]
Revenue, Major Customer [Line Items]
Revenues	(106)		263		(21)		485
Strativa [Member] | Total Strativa Revenues [Member]
Revenue, Major Customer [Line Items]
Revenues	$ 21,224		$ 21,739		$ 41,529		$ 44,947

[1] No single product in the other category is in excess of 3% of total generic revenues for the six-month period ended June 30, 2012 or for the six-month period ended June 30, 2011.

[2] Other product related revenues represents licensing and royalty related revenues from profit sharing agreements related to products such as diazepam rectal gel, the generic version of Diastat®, and fenofibrate, the generic version of Tricor®. Other product related revenues included in the Strativa segment relate primarily to Strativa’s share of the proceeds from Optimer Pharmaceuticals’ sale of certain rights in fidaxomicin to a third party.